EP0783580A2 - Nichtstruktureler leserrahmen i dna sequenz und protein aus menschlichem parvovirus b19 - Google Patents

Nichtstruktureler leserrahmen i dna sequenz und protein aus menschlichem parvovirus b19

Info

Publication number
EP0783580A2
EP0783580A2 EP95934630A EP95934630A EP0783580A2 EP 0783580 A2 EP0783580 A2 EP 0783580A2 EP 95934630 A EP95934630 A EP 95934630A EP 95934630 A EP95934630 A EP 95934630A EP 0783580 A2 EP0783580 A2 EP 0783580A2
Authority
EP
European Patent Office
Prior art keywords
protein
parvovirus
human parvovirus
dna sequence
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95934630A
Other languages
English (en)
French (fr)
Inventor
Hans Wolf
Andreas Von Poblotzki
Susanne Modrow
Andreas Gigler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wolf Hans Joachim
Original Assignee
Wolf Hans Joachim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wolf Hans Joachim filed Critical Wolf Hans Joachim
Priority to EP95934630A priority Critical patent/EP0783580A2/de
Publication of EP0783580A2 publication Critical patent/EP0783580A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14211—Erythrovirus, e.g. B19 virus
    • C12N2750/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to DNA sequences of the human parvovirus B19 (human parvovirus B19) genome coding for the non-structural protein designated NS-1 and the encoded protein for use in any kind of active or passive vaccination, as a pharmaceutical composition, or as part of a diagnostic composition with special emphasis on the detection of antibodies directed against this protein in infected persons.
  • This facilitates the diagnosis and treatment of a human parvovirus B19 infection with severe complications like e.g. arthritis and aplastic crisis associated with this virus.
  • this protein relates to the use of this protein for the production of specific antisera, antibodies or antibody related proteins in animals or other appropriate systems and their use for diagnostic or pharmaceutical purposes especially for the detection of the antigen in infected cells.
  • the human parvovirus B19 causes a variety of clinically different illnesses in the infected person. The most common picture is the so called erythema infectios ⁇ m or fifth disease (Anderson et a!., 1985). In immunocompromised people or people with need for an elevated erythropoesis, the virus may cause severe aplastic crisis. The outcome of infection in such cases may be lethal. This may also happen if a human parvovirus B19 infection is aquired during pregnancy, since the virus has been shown to be embryopathic by causing fetal hydrops.
  • SUBSTITUTE SHEET (RULE 261 precursor cells in the bone marrow of the infected individual. This leads to destruction of these cells, the complete shutdown of erythropoesis and high titer viraemia.
  • the virus is thought to be cleared rapidly by the humoral immune response after viraemia followed by the restoration of erythropoesis in the bone marrow. This picture had to be modified for findings in the last years, where the virus was shown to be present in different tissues of the host for prolonged time spans (Saal et al., 1992; Patou et al.; 1992; Foto et al., 1993; Cassinotti et al.,
  • the diagnosis of infection with human parvovirus B19 is usually based on the detection of antibodies against the structural proteins VP1 and VP2 by ELISA,
  • This relates to the presence of antibodies against the NS-1 protein as well as to direct demonstration of the protein itself.
  • the production of specific antisera or antibodies against the NS-1 protein allows the detection of the antigen in any kind of cells of the patients. Detection of the NS-1 protein points to an active viral genome in the cell even in the absence of measurable virus titers in the patient sera. This accounts especially for the investigation of bone marrow cells, where the presence of viral DNA has been described, whereas at the same time no virus has been found in the serum by PCR (Foto et al., 1993). It was one aim of the current invention to develop a new assay for cases in which atypical infection leads to severe clinical complications.
  • a further object of the invention was to isolate the DNA sequence coding for the parvovirus B19 NS-1 protein. This sequence was used for cloning and expression of the non-structural protein NS-1 in different expression systems. Its suitability for the detection of antibodies in sera from patients with human parvovirus B19 associated complications and suspected persistent infection was demonstrated.
  • the current invention relates to the use of a DNA sequence coding for a protein having the biological activities of human parvovirus B19 NS-1 protein and a protein having the biological activities of the non-structural protein NS-1 of the human parvovirus B19 (Fig. 1 ).
  • the NS-1 protein is the first protein expressed during the course of an infection with the human parvovirus B19 and functions during the replication of the virus.
  • Biological activities ascribed to this protein include a helicase, an ATPase, and a transcriptional regulation activity. Additionally this protein has been described as cytotoxic for the host cell. It is encoded in the left half of the human parvovirus B19 genome.
  • the invention relates to the antigenic properties of this protein and to the detection of the genome or transcripts thereof by hybridization with a DNA or RNA strand as a probe in standard hybridization techniques e.g. Southern or Northern blotting or in situ hybridization.
  • standard hybridization techniques e.g. Southern or Northern blotting or in situ hybridization.
  • the finding of abundant transcripts coding for NS-1 in the infected tissues can be taken as an indicator of deregulation of the genome and an atypical course of infection.
  • the invention relates to the cloning of the sequence coding for a protein having the biological activities of NS-1 into another DNA sequence for example the bacterial plasmid pQE40 (Fig 4, 5) or the baculovirus transfer vector pVL1392 (Fig 4, 5)
  • promotors suited for this purpose are the bacterial lac-promotor of the ⁇ -galactosidase operon for the expression in bacteria, the polyhednn promotor of baculoviruses for the expression in insect cells or the cytomegalovirus promotor for the production in many types of mammalian cell lines
  • the protein can be produced in different hosts e g the bacterium E coli, the yeast
  • E coli process the expression is induced by addition of an inducer, usually IPTG for the lac-operon Afterwards the cells can be harvested by cent ⁇ fugation, lysed and the protein can be recovered by affinity chromatography or other standard protein purification techniques Short ammo acid sequences of the protein can be obtained by chemical syntheses of peptides These synthetic peptides may comprise important immunological target sequences
  • the purified protein or the synthetic peptides can be used for the production of antibodies in rabbits and mice by immunization Especially the generation of monoclonal antibodies by the hybndoma technique which may be further modified to contain the NS-1 specific V- region fused to human C-domains is of advantage in the current invention Specific antibodies can be obtained alternatively by the phage display technique
  • This invention relates further to the diagnosis, treatment and prevention of the infection with human parvovirus B19
  • the antibodies or antibody related molecules described above can be used in pharmaceutical compositions for the treatment of diseases caused by the human parvovirus B19 Besides the typically harmless fifth disease, the human parvovirus B19 causes a series of more severe symptoms An infection associated arthritis, aplastic crisis in patients with underlying hematopoetic or immunological disorders or immunosuppressed patients and fetal hydrops are the most frequent problems encoutered during infection with human parvovirus
  • parvovirus B19 has been associated with some cases of meningitis or enteroco tis Since some of these diseases are associated with the persistence of the virus and the fact that the non-structural protein NS-1 is the most likely protein expressed from the viral genome in such cases, the pharmaceutical composition described above can be used for a therapeutical approach in these patients e g by immunoglobuhn mediated cure of viral infection In this context, the mouse-human chime ⁇ c antibodies mentioned before are of special interest
  • a pharmaceutical composition according to the current invention can be used for vaccination studies to prevent infection with parvovirus B19 This can be done by using this composition for passive immunization of people at risk of exposure
  • Another part of the invention is the use of the DNA sequences, recombinant proteins or synthetic peptides and the antibodies or antibody related molecules generated by the use of the proteins or peptides and a kit for the diagnosis of infection with human parvovirus B19
  • the DNA sequences or other probes able to hybridize to the viral genome or transcripts therefrom can be used in a kit for in situ hybridization to bone marrow smears or other tissue samples of the person with suspected infection
  • Another possibility is the use of such probes in dot-blot tests
  • Such a kit contains all buffers and probes necessary for successful detection of the viral genome or transcripts thereof as markers for the presence of the virus
  • the recombinant proteins or synthetic peptides can be used for the detection of specific antibodies in the sera or other body fluids of such persons
  • Fig 1 DNA sequence of human parvovirus B19
  • the left side of the human parvovirus B19 genome sequence from nt 200 to 2700 is shown (Shade et al 1986)
  • the translation of the NS-1 protein (nt 436-2451 ) gene is shown below the nucleotide sequence
  • the NS-1 open reading frame or subfragments corresponding to the ammo acid positions 1 -303, 150-303, 150-402, 304-492, 403-671 , 493-671 were amplified by PCR and inserted into the vector pQE40
  • Fig 2 Nucleotide sequences of the primers used for the amplification of different parts of the human parvovirus B19 NS-1 protein The designations of the amplified sequences are the same as for the protein parts Underlined nucleotides represent the endo ⁇ uclease recognition sites used for the insertion of the resulting PCR fragments in the bacterial expression vector pQE40 or the baculovirus transfer vector pVL1392 Nucleotides shown in italics are homologous to the published sequence of the human parvovirus B19 genome (Shade et al , 1986)
  • a schematic drawing of the human parvovirus B19 genome is shown on the top
  • the left part of the human parvovirus B19 genome coding for the NS-1 protein was amplified with different sets of primers
  • the specific primers used are indicated for each insert (full arrows) Names of the inserts are as listed at the left and the number of the first and last ammo acid contained is given
  • the resulting products were cloned in the plasmid pQE40 by the appropriate restriction endonucleases
  • the recognition sequences for the enzymes were introduced by the PCR primers and are indicated at the left and right ends of the open reading frames (open boxes open reading frames, K Kpn I, S Sal I, X Xho I, B.
  • Fig.4 Expression of recombinant NS-1 protein in procaryotic and eucaryotic cells. SDS-PAGE analysis of the bacterial lysates before (lane 2, -IPTG) and after induction of expression (lane 3, +IPTG). E. coli strain SG13009[pREP4] containing plasmid pQE40NS-1 was grown in LB- medium in the presence of 50 ⁇ g/ml kanamycin and 100 ⁇ g/ml ampicilli ⁇ to an OD 600 of 0,4 and expression of the recombinant protein was induced by addition of 1 mM IPTG for 3 hours. After separation on a SDS-PAGE gel the gel was stained with Coomassie-blue. Clearly a band corresponding to the 71 kD NS-1 protein is visible after induction (lane 3: +IPTG). A molecular weight standard is shown at the left side (lane 1 : marker), molecular weights are as indicated.
  • Fig.5 Expression of the NS-1 fragments in E. coli.
  • E. coli strain SG13009[pREP4] was transformed with plasmids pQE40NS/A; pQE40NS/B; pQE40NS/C; PQE40NS/D or pQE40NS/E and pQE40NS/F.
  • Transformed bacteria were grown in LB-medium containing 50 ⁇ g/ml kanamycin and 100 ⁇ g/ml ampicillin until an OD ⁇ oo of 0,6 was reached and induced for 5 hours with 1 mM IPTG.
  • Bacteria were harvested, lysed in boiling mix (50mM Tris-CI pH 7,0; 100mM dithiothreitol; 2% SDS; 0,1 % bromphenolblue; 10% glycerol) and analyzed by SDS-PAGE and subsequent Coomassie-blue staining.
  • Lane 1 molecular weight marker
  • lane 2 pQE40NS/A
  • lane 3 pQE40NS/B
  • lane 4 pQE40NS/C
  • lane 5 pQE40NS/D
  • lane 6 pQE40NS/E
  • lane 7 pQE40NS/F lane 8: SG13009 before induction.
  • Fig.6 Expression of the NS-1 protein in insect cells infected with NS-1 recombinant baculovirus.
  • Sf-9 cells were infected with 0,1 m.o.i. of N3-1 recombinant baculovirus and incubated for four days under standard conditions. The cells were harvested at day four and lysed in boiling mix (50mM Tris-CI pH 7,0; 100mM dithiothreitol; 2% SDS; 0,1 % bromphenolblue; 10% glycerol). The lysates were seperated on a SDS- PAGE gel and transferred to a nitrocellulose membrane Detection was done with a NS-1 specific rabbit serum by a standard Western blot procedure
  • Microtiter plates were coated with 50ng/well of the recombinant NS-1 protein The sera were assayed in a 1 100 dilution A rabbit anti-human IgG serum was used for the detection of specific IgG in the patients sera Serum 2,10 and Ra, all from patients with a severe B19 associated arthritis are the only probes containing specific antibodies Sera from previously not infected people or patients with acute or past B19 infection without reported complications did not show any reactivity
  • Detection of specific antibodies in patients with persistent infection Sera collected from two patients with persistent parvovirus B19 infection were investigated These patients contain specific IgG and IgM antibodies as demonstrated by the ELISA test Dates of the probe collection are given Fig.10: Efficient generation of NS-1 specific antisera in rabbits.
  • Blood was obtained four weeks after the last boost injection and the prepared serum was tested in 1 :200 dilution against recombinantly expressed fragments of NS-1 on a Western blot. Detection was done with an alkaline phophatase coupled anti-rabbit antibody. Specific protein bands of the molecular weight corresponding to the NS-1 fragments are recognized by the antibodies in that serum.
  • Fig. 11 Development of NS-1 protein specific antibody titers.
  • Example 1 Expression of recombinant NS-1 protein in E. coli
  • the part of the human parvovirus B19 genome corresponding to the NS-1 open reading frame (Fig. 1 ) was amplified by a polymerase chain reaction with primers pB19NS-NL (corresponding to nucleotide positions 435-453 in the sequence published by Shade et al. (Shade et al. 1986)) and primer pB19NS- NR (Fig. 2, 3) (corresponding to nucleotide 2430-2451 ).
  • a Kpn I restriction site was introduced via the primer at the 5 ' -end and a Xho I site was generated at the 3 ' -e ⁇ d the same way (Fig. 1 ). After 35 cycles amplification at 94°C for 30 sec / 42°C for 30 sec / 72°C for
  • plasmids of the pQE series offer the advantage of efficient repression of expression in the absence of an inducer due to the presence of multiple copies of the lac-repressor target sequence upstream of the gene of interest
  • the repressor protein is provided in trans by overexpression from a second plasmid [pREP4] in the same host cell, when strain SG13009 is used
  • the subgenic fragments NS-A, NS-B, NS-C, NS-D, NS-E and NS-F were generated following the same principles (Fig 5) NS-A had to be expressed as a fusion protein to the mouse DHFR gene for efficient production in this system
  • each plasmid the protein is fused to the ammo terminal six histidines
  • the plasmids were transformed into E coli strain
  • Example 2 Purification of the recombinant protein.
  • the specificity of the eluted protein was tested by electrophoretic transfer of the proteins on a nitrocellulose membrane (Western blotting) and detection with NS-1 specific rabbit antisera according to standard procedures (Maniatis et al., 1989). The peak fractions were pooled and loaded on a preparative SDS-PAGE column for further purification.
  • the resolution gel concentrations were 10% acrylamide/bisaycrylamide (29:1) for the whole protein and 12,5% for the smaller proteins.
  • the column consisted of a 1cm stacking gel
  • SUBSTITUTE SHEET (RULE 261 and a 6,5 cm resolution gel and was run at 40mA. The collection of fractions was started when the running front of the probe reached the lower end of the column. 2,5 ml fractions were collected and the protein peak was localized by measuring the UV light adsorption of the solution. The peak fractions were analyzed exactly as described above for the Ni-Agarose column.
  • the purified protein can be used to detect antibodies against the NS-1 protein in humans infected with the human parvovirus B19.
  • the purified proteins (appr. 50ng) were run on a 15% SDS-PAGE gel and transferred to a nitrocellulose membrane according to standard protocols (Towbin et al., 1979). Subsequently the membrane was blocked with 5% low-fat dry milk solubilized in Tris-buffered saline pH 7,5 for 1 hour at room temperature and incubated with the patients sera diluted 1 :200 in Tris-buffered saline pH 7,5 overnight at room temperature. The membranes were washed three times with Tris-buffered saline pH 7,5 / 0,5% TWEEN 20 for 15 min. at room temperature before the second antibody was added.
  • the second antibody was a Peroxidase coupled anti-human ⁇ -chain antiserum raised in rabbits (P215; DAKO GmbH, Germany) or an alkaline phosphatase coupled rabbit antiserum to human IgG ⁇ -chains (BioRad GmbH, Germany). After incubation at room temperature for 2-3 hours the blots were washed again with Tris-buffered saline pH 7,5/ 0,5% TWEEN 20 and, for the alkaline phosphatase staining, equilibrated in 0,2M Na-carbonate buffer pH 9,2 / 5mM MgCI for 10 min., room temperature. Colour development was done according to standard procedure using diami ⁇ obenzidine for the
  • SUBSTITUTE SHEET (RULE 26 ⁇ peroxidase and BCIP/ NBT as substrate for the alkaline phosphatase (Ma ⁇ iatis et al., 1989).
  • NS-1 protein by ELISA reaction plates (Greiner flat bottom F plates; medium binding capacity) were coated with 50ng of the purified recombinant protein in a total volume of 50 ⁇ l per well in
  • Patient A a 77 year old female, suffered from recurrent granulocytic aplasia and has been described previously (Pont et al , 1992)
  • Sera were tested for the presence of antibodies to parvovirus B19 capsid proteins VP1 and VP2 by different capture ELISA tests using isolated B19 vi ons and a monoclonal antibody to parvovirus B19 (VRL/B19/11 ) (Schwarz et al., 1988). Confirmative testing for patient A by RIA was performed by B.J. Choen, Virus Reference Laboratory, London.
  • Antibodies to the non-structural protein NS-1 were tested retrospectively with an ELISA based on recombinant protein as described in Example 3 and in Poblotzki et al., 1995.
  • Viral DNA was detected by dot-blot analysis as described previously (Pont et al., 1988). Briefly 5 ⁇ l o f serum were dotted on a nylon membrane and detected accord to the manufacturers protocol using digoxigenin labelled 700bp DNA fragments from the viral genome as hybridization probe (Boehringer Mannheim GmbH, Penzberg, Germany). This test allows detection of virus concentrations with more than 10 7 particles per mL serum. A nested PCR assay was set up using pairs of primers from the region of the B19 genome coding for the capsid proteins (outer primers nt 2901- 2918 and 3511 -3529, inner primers nt 2956-2972 and 3431-3448)
  • Patient A has NS-1 specific antibodies present in serum samples drawn after a first admission to the hospital due to an anemia without significant impairment of the white cell counts She also had IgM and IgG specific for B19 capsid protein at this time (Fig 1 1 , patient A) At renewed admission ten months later severe granulocytopenia without significant impairment of red cell counts was found (Pont et al , 1988) Concomitantly the patient developed a strong rise in the IgG response to NS-1 protein After intravenous treatment of the infection with high-titered immunoglobulms to the capsid proteins, IgM titers to NS-1 rapidly declined while IgG remained detectable In contrast, the antibodies against the capsid proteins remained detectable for about four weeks only (Fig 11 A, patient A VII/89) After four months virus-specific DNA was still present in the serum, but neither IgM nor IgG directed to the capsid protein were found A second period of severe agranulocytosis was accompanied by a moderate rise of
  • Patient C developed antibodies specific to the parvovirus B19 capsid proteins during a period of complete bone marrow aplasia and febrile illness No significant impairment of the white cells was found, viral DNA was detectable by hybridization for an unusually long time of about four weeks and remained detectable by nested PCR
  • the IgM titer specific for the NS-1 protein was only 1 64 but IgG was clearly detectable After resolution of the aplasia, IgM specific for capsid proteins disappeared Several months later, a rise in NS-1 specific IgG and also a moderate elevation of the IgM concentrations were observed (Fig 11 C, patient C XI/90) without obvious clinical manifestations
  • NS-1 specific antibodies were not observed in a panel of control sera from patients with acute erythema mfectiosum Even in sera taken directly after the onset of disease that contained IgM and IgG specific for the capsid proteins, antibodies specific for the NS-1 protein were not detected Additionally, we could not find NS-1 specific antibodies in sera from patients with serological evidence for past infections or without previous exposure to parvovirus B19
  • SUBSTITUTE SHEET (RULE 261 (patient B) had been known to be immu ⁇ ocompromised before the onset of disease which makes the basis of persistence difficult to explain. So far, no abnormalities of the immune system could be found besides the initial failure in patients A and B to generate a stable IgG response to the capsid proteins. In all three cases parvovirus B19 replication was indicated by the prolonged presence of high concentrations of viral DNA in the sera, that were detectable by dot-blot hybridization. In contrast to sera from patients with acute erythema infectiosum these patients developed a humoral immune response to the NS-1 protein. Patients A and B have high IgM titers at the beginning of infection, whereas patient C displayed only low specific IgM values (Fig. 11 ). For this case there was evidence for the presence of viral DNA in a serum sample drawn about six months earlier, which unfortunately was not available for this study. This could mean, that the IgM response has declined already in the first sample investigated here.
  • NS-1 specific antibodies may reflect an elevated production of this protein in the cases described.
  • non-erythroid cells bearing the receptor for parvovirus B19 but normally less susceptible for infection might become infected (Brown et al., 1993).
  • the regulation of viral gene expression is strongly shifted towards preferential production of NS-1 protein that is cytotoxic (Lin et al., 1992; Ozawa et al., 1988).
  • the abortive infection of these cells would have two consequences: an elevated synthesis of NS-1 protein and its release after cell death. This would result in efficient induction of an NS-1 specific humoral immune response.
  • NS-1 specific IgG antibodies to the capsid proteins VP1 and VP2 were not detectable in patients at all time points of investigation. Therefore we suggest that analysis of NS-1 specific antibodies could help to confirm the role of parvovirus B19 in cytopenias or bone marrow aplasia, particularly since viral DNA is often difficult to detect in sera from those persons. Furthermore, the data presented in the Examples emphasis the role of NS-1 specific antibodies as a useful means for the detection of a prolonged or persistent B19 infection.
  • test for NS-1 specific antibodies can, in such cases facilitate an exclusion diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP95934630A 1994-09-22 1995-09-22 Nichtstruktureler leserrahmen i dna sequenz und protein aus menschlichem parvovirus b19 Withdrawn EP0783580A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP95934630A EP0783580A2 (de) 1994-09-22 1995-09-22 Nichtstruktureler leserrahmen i dna sequenz und protein aus menschlichem parvovirus b19

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94114973 1994-09-22
EP94114973 1994-09-22
EP95934630A EP0783580A2 (de) 1994-09-22 1995-09-22 Nichtstruktureler leserrahmen i dna sequenz und protein aus menschlichem parvovirus b19
PCT/EP1995/003758 WO1996009391A2 (en) 1994-09-22 1995-09-22 Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19

Publications (1)

Publication Number Publication Date
EP0783580A2 true EP0783580A2 (de) 1997-07-16

Family

ID=8216310

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95934630A Withdrawn EP0783580A2 (de) 1994-09-22 1995-09-22 Nichtstruktureler leserrahmen i dna sequenz und protein aus menschlichem parvovirus b19

Country Status (3)

Country Link
EP (1) EP0783580A2 (de)
AU (1) AU3698595A (de)
WO (1) WO1996009391A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771751B1 (fr) 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris Erythrovirus et ses applications
US6642033B1 (en) * 1999-07-20 2003-11-04 V.I. Technologies, Inc. Nucleic acids for detecting parvovirus and methods of using same
CZ308201B6 (cs) 2001-06-28 2020-02-26 Grifols Worldwide Operations Limited Diagnostické zkoušky pro parvovirus B19
AU2002323520B2 (en) 2001-08-31 2008-02-21 Gen-Probe Incorporated Assay for detection of human parvovirus B19 nucleic acid
US20060057643A1 (en) * 2004-09-10 2006-03-16 Mccarthy Laurence R Methods and compositions for detecting erythrovirus genotypes
EP2401287B3 (de) 2009-02-26 2018-09-26 Gen-Probe Incorporated Assay zum nachweisen menschlicher parvoviren-nukleinsäure
WO2012117382A1 (en) * 2011-03-03 2012-09-07 Novartis Ag Method for detecting parvovirus antigen
AU2012284307A1 (en) 2011-07-15 2013-05-09 Gen-Probe Incorporated Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acids in single-plex or multiplex assays
CN103849630B (zh) * 2014-03-17 2016-01-13 北京英诺特生物技术有限公司 一种重组人细小病毒b19蛋白及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07147986A (ja) * 1992-09-24 1995-06-13 Denki Kagaku Kogyo Kk ヒトパルボウイルス遺伝子、それによってコ−ドされるポリペプチド及び用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9609391A3 *

Also Published As

Publication number Publication date
WO1996009391A2 (en) 1996-03-28
AU3698595A (en) 1996-04-09
WO1996009391A3 (en) 1996-08-29

Similar Documents

Publication Publication Date Title
US6509019B1 (en) Immunologically active proteins from Borrelia burgdorferi
ES2350491T3 (es) Antígenos y vacunas para el streptococcus pneumonia.
DK173205B1 (da) Fremgangamåde til detektering af Haemophilus influenzae og vaccinepræparat indeholdende Haemophilus influenzae.
US7605248B2 (en) Recombinant constructs of Borrelia burgdorferi
Kim et al. High-level expression of a 56-kilodalton protein gene (bor56) of Rickettsia tsutsugamushi Boryong and its application to enzyme-linked immunosorbent assays
KR100318516B1 (ko) Ｅ형 간염 파키스탄형 균주의 재조합 단백질 및 이를이용한 진단방법과 백신
KR20010052767A (ko) 백신
JP2776633B2 (ja) ストレプトコッカス・スイスの病毒性をコードするｄｎａ配列，該ｄｎａ配列の一部，該ｄｎａ配列に由来するポリペプチドおよび抗体
US20030059894A1 (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
Zuffi et al. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans
Centurion-Lara et al. Conservation of the 15-kilodalton lipoprotein among Treponema pallidum subspecies and strains and other pathogenic treponemes: genetic and antigenic analyses
EP0783580A2 (de) Nichtstruktureler leserrahmen i dna sequenz und protein aus menschlichem parvovirus b19
EP0524958A1 (de) Antigen-wirkende proteine von -i(borrelia burgdorferi).
KR100527070B1 (ko) 치주염의진단및치료용포르피로모나스긴기발리스항원
CA2167691A1 (en) Campylobacter jejuni antigens, and methods for their production and use
CA2075366C (en) Immunologically active peptides or polypeptides from the parvovirus b19
US20040071713A1 (en) Psedomonas aeruginosa antigens
WO1996002648A9 (en) Lkp pilin structural genes and operon of nontypable haemophilus influenzae
WO1996002648A1 (en) Lkp pilin structural genes and operon of nontypable haemophilus influenzae
Feng et al. A 55-kilodalton antigen encoded by a gene on a Borrelia burgdorferi 49-kilobase plasmid is recognized by antibodies in sera from patients with Lyme disease
KR100359526B1 (ko) E형간염파키스탄형균주의재조합단백질및이를이용한진단방법과백신
DK175072B1 (da) Rekombinant DNA-molekyle, værtscelle transformeret dermed, fremgangsmåde til fremstilling af et polypeptid ved anvendelse af det rekombinante DNA-molekyle, og diagnostisk sæt omfattende et sådant polypeptid
Lederman et al. Detection of bovine parvovirus proteins homologous to the nonstructural NS-1 proteins of other autonomous parvoviruses
WO1995035114A1 (en) Borrelia burgdorferi exported plasmid protein a, nucleic acids encoding thereof, and uses thereof
US5556755A (en) Method for detecting Branhamella catarrhalis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970422

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): DE FR GB IT SE

17Q First examination report despatched

Effective date: 20011115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060331